Tinzaparin has FDA-approved labeling for use in the treatment of acute symptomatic DVT with or without PE when administered in conjunction with warfarin sodium. An advantage of tinzaparin, like all ...
(HealthDay News) — For patients with active cancer and acute symptomatic venous thromboembolism (VTE), full-dose tinzaparin does not reduce recurrent VTE compared with warfarin, according to a study ...
Objective and Design: Tinzaparin and dalteparin are low molecular weight heparins (LMWHs) with different pharmacokinetic and pharmacodynamic profiles that may lead to differences in efficacy and ...
Hospitalization rate differences among cancer patients on biologics and biosimilars. HTB patients with active LC related to 4 factors: disease, treatment, biomarker and patient features.
COVID-19 infections among minority patients with gastrointestinal malignancies in urban safety net academic medical centers. Thrombosis risk factors related to cancer, treatment, biomarker and patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results